van Poelgeest, Mariette I E <br/><br/>
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.  [electronic resource] 

 -  Journal of translational medicine  Apr 2013 
 - 88 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1479-5876 
<br/><br/><label>Standard No.: </label>10.1186/1479-5876-11-88  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antineoplastic Agents--therapeutic use<br/>Cell Proliferation<br/>Cytokines--immunology<br/>Female<br/>Genital Neoplasms, Female--therapy<br/>Human papillomavirus 16<br/>Humans<br/>Immunotherapy--methods<br/>Middle Aged<br/>Oncogene Proteins, Viral--immunology<br/>Papillomavirus E7 Proteins--immunology<br/>Papillomavirus Vaccines--immunology<br/>Recurrence<br/>Regression Analysis<br/>Repressor Proteins--immunology<br/>Uterine Cervical Neoplasms--therapy<br/>Vaccines, Subunit--therapeutic use